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1 Executive Summary
1.1 Challenge Overview
Cancer immunotherapy (CIT) is a promising new type of cancer treatment that 
uses the patient’s own immune system to fight cancer cells. CIT drugs work to 
stop the cancer cells from turning off the immune system’s T-cells by inhibiting 
the PD-L1 produced by the tumour cells (PD-L1 is a protein that binds to PD-1 
receptors on T-cells and prevents the immune system from attacking the cancer 
cells).
CIT is currently being used to treat patients with non-small cell lung cancer 
(NSCLC) for whom chemotherapy or other drugs have failed. CIT is also be-
ing used as part of the first-line treatment in patients with advanced NSCLC 
(aNSCLC - stage III and higher). Theoretically, patients with high PD-L1 ex-
pression levels are more likely to respond well to CIT; however, in practice, 
patient outcomes vary considerably.
In this data study group, we investigated different approaches for predicting 
survival time for patients treated with CIT as first line of treatment, using both 
electronic health records and tumour genomic data. We also investigated the 
causal effects of CIT vs other oncology treatments, and studied treatment 
heterogeneity. The results contribute to identifying patients who are most likely 
to benefit from CIT.
1.2 Data Overview
Two main datasets, provided by the Roche, were used in this data study:
1. Electronic health records of 51,884 aNSCLC patients, collected by Flatiron
Health, Inc. from over 280 clinics across the United States. This dataset
contains data on patients’ demographics, diagnosis, line(s) of therapy re-
ceived (including medications administered), lab test results, progression
and mortality. We will refer to this dataset as the ‘EDM’ dataset.
2. Electronic health records and genomic data by Foundation Medicine, Inc.
for a subset of 5,866 aNSCLC patients in the EDM dataset. This dataset,
in addition to the tables present in the EDM dataset, contains data on pa-
tients whose clinicians requested Foundation Medicine biomarker testing,
and includes all classes of mutation in approximately 400 genes, compu-
tationally determined ancestry, therapy details and tumour response. We
will refer to this dataset as the ‘FMI’ dataset.
Note that these datasets had to be analysed separately, as even when they
contain the same patients, identifiers in each of the two datasets are different
(by design).
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1.3 Main Objectives
The overall aim of this data study was to explore various methods for predicting
patient survival after CIT using electronic health records and genomic data.
Specifically, we sought to answer the following questions:
1. Which model most accurately predicts patient survival after CIT initi-
ation? and does adding genomic features to demographics and clinical
variables improve the accuracy of the models?
2. Which treatment option (CIT or chemotherapy) is likely to be more effec-
tive in aNSCLC patients?
3. Are there subgroups of patients who benefit more from CIT?
1.4 Approach
To answer the first question (see Section 1.3), we performed:
• Modelling of the relationship between variables using probabilistic classi-
fication models;
• Binary prediction of patient survival using random forests;
• Estimation of patient survival using the Kaplan-Meier estimator;
• Statistical analysis of baseline and time-varying factors using the Cox
regression model and dynamic prediction of patient survival using joint
longitudinal-survival models.
To answer the second question, we compared different treatment options (CIT,
chemotherapy, combination) using a formal potential outcomes framework, to
obtain the average causal treatment effect. Assuming we have enough variables
to control for the confounding between CIT-treated and not treated, we esti-
mated the causal effects of CIT on 6-month survival, by targeted maximum
likelihood estimation, combined with SuperLearner, an ensemble method, that
included random forests and gradient boosting amongst the candidate learners.
Finally, to answer the third question, we performed:
• Dimensionality reduction and cluster analysis using spectral clustering and
the PAM algorithm;
• Data visualisation using the t-SNE algorithm;
• Cluster analysis using an integrative approach;
• causal forests, to characterise the factors most strongly associated with
heterogeneity of the causal treatment effect comparing CIT to other treat-
ments.
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1.5 Main Conclusions
The results of binary prediction and estimation of patient survival revealed
the lab tests (including Albumin, Calcium, Creatinine and Haemoglobin levels)
done prior to the initiation of CIT as first-line treatment to be highly predictive
of survival, while demographics (e.g., smoking history) were found to be not
of predictive relevance in the fitted models. These results agree with those of
dynamic prediction of patient survival.
Furthermore, adding the genomic data did not improve the quality of binary
predictions. Similarly, analysis of the data using unsupervised methods (cluster
analysis and data visualisation) with and without the genomic data showed that
without the genomic features, better clusterings are obtained.
The results of comparing different treatment options showed that having im-
munotherapy as part of the treatment (vs chemotherapy alone) increases the
patient survival time and hence, treatment options that include immunother-
apy are likely to be more effective.
1.6 Limitations
We encountered the following limitations regarding the data and the methods
that were applied:
• Missing data;
• The EDM and FMI datasets are not linkable and hence were processed
separately;
• The bias introduced in the data as a result of genetic data being available
for only a subset of patients;
• The data are observational and hence, causal inferences are subject to
strong unverifiable assumptions holding;
• Lack of a ‘control group’ and no validation dataset that we could use to
benchmark the methods.
1.7 Recommendations and Future Work
Below is a summary of the future research avenues proposed:
• Additional data pre-processing to address data quality issues;
• Including additional variables in the models;
• Optimising the methods that were applied to the data;
• Extending the analyses to other patient cohorts;
• Validating the results in intervention trials.
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2 Quantitative Problem Formulation
Our main task in this data study was to develop accurate models for predicting
patient survival time from the initiation of treatment, as well as to identify
factors that are predictors of survival time. Given that the outcome variable is
time from treatment initiation until the patient’s death, this problem falls into
the domain of survival analysis. Moreover, survival analysis methods can handle
censored (or incomplete) observations, one of the limitations of this dataset.
To exploit the large collection of existing machine learning tools, we considered
a simplified version of this task by focusing on predicting binary survival (alive
or dead) at 6 and 12 months for a cohort of patents who had received CIT as
first-line treatment. Two categories of models commonly used for this task are:
probabilistic classification models (e.g., regression models to model the survival
time as a function of a set of predictor variables) and decision trees (e.g., random
forests).
We then considered the more complex task of dynamically predicting survival
time. Three easy-to-interpret models widely used for this task are: the Kaplan-
Meier estimator, which can be used to estimate survival probabilities as a func-
tion of time and compare survival curves for two or more groups of patients; the
Cox proportional hazards regression model, which allows testing for differences
in survival times of two or more patient groups while allowing to adjust for
covariates of interest; and joint longitudinal-survival models for studying the
association between time-updated variables (e.g., monthly lab test results) and
survival time.
In addition to supervised methods, we also considered the application of un-
supervised methods such as cluster analysis and data visualisation. We began
with clustering and dimensionality reduction techniques as the data are high-
dimensional. We then employed an integrative clustering approach. In integra-
tive cluster analysis, we assume the data arise from multiple sources (e.g., if we
aim to infer groups of patients, data for each patient are available across a num-
ber of datasets). Such approach is commonly used in the analysis of genomic
datasets wherein we observe multiple measurements for patients (e.g., mRNA,
microRNA, reverse phase protein arrays, DNA methylation, somatic copy num-
ber alterations, etc.). It may not be suitable to model such datasets as arising
from a common family of statistical distributions and so we cannot simply con-
catenate these data and analyse them using standard clustering methods such
as k -means or hierarchical cluster analysis.
Our other task in this data study was to compare the effect of CIT to that
of other treatment options on patients’ survival. For this task, it is important
to recognise that the data arose from routine clinical practice, so the patients
receiving CIT as first-line, are very likely to be systematically different in their
baseline characteristics to those not receiving it in terms of, for example, their
disease severity, age, lab results and even socioeconomic status. These baseline
characteristics which are simultaneously associated with the treatment received
and survival time are referred to as confounders. Assuming we control for all the
confounders, we performed causal inference to estimate the average causal treat-
ment effect of CIT vs the rest (adjusting for the confounding by using inverse
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probability of treatment weights). We then studied treatment effect heterogene-
ity, and described the covariates which are most associated with heterogeneous
causal effects. These covariates are potential effect modifiers (subgroup effects
that should be investigated in future studies).
3 Dataset Overview
3.1 Data Preparation
The datasets provided by Roche contain clinical data for over 50,000 aNSCLC
patients, of whom around 6,000 have had genomic profiling. For this subset,
clinical and genomic data were linked at the individual patient level, resulting
in a rich clinico-genomic database.
The data for this data study were prepared as follows: First, patient identifiers
and demographics for qualifying patients (e.g., patients who received CIT as
first-line treatment) were extracted. Next, relevant index dates (e.g., start date
of CIT) were created, and for each patient, baseline lab and clinical data were
extracted, defined as the last measurement recorded prior to the index date.
These variables were merged with the patients’ demographic data. The following
prognostic factors that characterise patients with lung cancer, identified from
the literature [1], were considered:
• Age
• Gender (higher treatment success rate in females)
• Histological type of cancer
• Co-morbidities
• Smoking history
• Additional malignancies (in particular neuroendocrine tumours)
• Insurance category (a good proxy for socioeconomic status)
The following lab variables were also chosen according to the literature [1]:
• Albumin levels (kidney/liver function)
• Creatinine levels (kidney/liver function)
• Haemoglobin levels (blood disorders)
• Calcium levels (thyroid tumour indicator)
• Lactate Dehydrogenase (cell damage indicator)
• Neutrophil count (immune system response)
• Leukocyte count (immune system response)
• Lymphocytes (immune system response).
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These factors are re-measured over time, so baseline and time-updated versions
were extracted and used in accordance with the goal of the corresponding anal-
yses.
Genomic data preparation
The PD-L1 expression level, a key indicator of immune response, was processed
as follows: we mapped the ‘PercentStaining’ and ‘ExpressionLevel’ variables to
the same categories: <1% to PD-L1-NEGATIVE, 2%-49% to PD-L1-LOW and
50%-100% to PD-L1-HIGH. Of the two variables, we chose ‘ExpressionLevel’ as
the PD-L1 expression level if it existed, and chose ‘PercentStaining’ otherwise.
This is due to the staining being less precise.
Missing values, resulting from the cases where the patient never had a test
or the date of the test is unknown, were coded as ‘Unknown’. Unfortunately,
baseline PD-L1 expression level was missing for many patients, so this variable
was ultimately discarded.
The genomic data from the FMI dataset were prepared from data generated by
six enrichment capture kits: CF2 (n=616), D2-R2 (n=2), DX1 (n=208), T4b
(n=35), T5a (n=494) and T7 (n=4511). While CF2 and D2-R2 captured free
circulating DNA and RNA from peripheral blood, all other kits were applied
to solid tumour samples. Since different gene panels covered different genes, in
order to exclude spurious correlations, analyses using these data were restricted
to patients whose DNA was sequenced using the T7 kit. The following variants
were included:
• Single nucleotide variants (SNVs)
• Copy number variants (CNVs)
• Non-human variants (NHs)
• Large rearrangements (REs)
These variants were transformed into a gene burden score (sum of variants
identified within each gene) for each variant type.
Note that when preparing the genomic data, we assumed equal burden and di-
rectionality of the variants. An optimal modelling of the genomic data would in-
clude biological variables such as variant zygosity (heterozygous or homozygous)
and rarity, tumour cellularity and whether a variant is germ-line or somatic.
Similarly, when modelling CNVs, we only reported if an abnormal number of
copy numbers had been identified. An improved version of this modelling would
include also the extent of duplications and their rarity.
In the last step of data preparation, we added the outcome (e.g., survival, 6 and
12-month mortality) variables.
3.2 Data Quality Issues
• Some patients were lost to follow-up;
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• The lab test data for a large portion of patients were incomplete. The
analyses that required these data were performed on complete cases (also
known as list-wise deletion, i.e., patients were removed from the analyses
sets). This could potentially introduce biases to our results;
• For some patients, ethnicity data are missing;
• Using different tools for the genetic tests could potentially have introduced
bias into the genomic data.
4 Binary Prediction and Estimation of Patient
Survival
4.1 Task Description
In this section, we predicted survival for patients who received CIT as first-line
treatment and identified the variables associated with survival. To do this, we:
• Modelled the relationship between variables using probabilistic classifica-
tion models;
• Predicted binary patient 6-month survival using random forests;
• Estimated patient survival using the Kaplan-Meier estimator.
4.2 Experimental Setup
Data
For probabilistic classification models, lab test data and demographics from the
EDM dataset were used. As previously described (see Section 3.1), only patients
with all the 8 baseline lab variables and demographic data were included.
For binary predictions, clinical and genomic data from the EDM and FMI
datasets were used.
For estimating patient survival, a subset of observations for 7,700 patients from
the EDM dataset was used, including the follow-up time (in days) since the date
of the first round of CIT until the date of death, when it was present, or the
date of the last visit recorded otherwise. In the latter case, the observations
correspond to censored patients. The event indicator is thus set to 0, if patient
is censored and 1 otherwise. These data also included age, gender, smoking
status, histology and the results of any lab test done immediately before the
initiation of CIT.
Methods
Three probabilistic classification models with different penalisation schemes
were applied to the EDM dataset:
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Method Accuracy (t=0.3) Accuracy (t=0.8)
Binary GLM 0.887 0.843
RLR 0.887 0.877
LASSO 0.887 0.847
Table 1: Accuracies achieved by three probabilistic classification models on the EDM dataset
using two different thresholds
• A binary generalised linear model (GLM, logistic regression) with no pe-
nalisation;
• A ridge logistic regression (RLR) model that penalises large coefficients
and shrinks them towards zero to reduce overfitting;
• A LASSO logistic regression, which penalises the coefficients in such a way
that many of them are identically zero.
The penalty (for each penalised logistic regression) was chosen by 10-fold cross-
validation.
Random forest classifiers were applied to the EDM and FMI datasets. In ad-
dition, a random forest regressor was trained to predict patient survival time
(in days) for those who died within 6 months. The Kaplan-Meier estimator was
used to estimate patient survival time (in months) for a subset of patients from
the EDM dataset.
4.3 Results
Demographics were consistently considered unimportant by all probabilistic
classification models. The binary GLM model showed statistically significant
coefficients for Albumin (-ve), Haemoglobin (+ve), Calcium (+ve) and LDH
(+ve). The RLR model showed similar results, with additional strong posi-
tive associations with Creatinine, Leukocytes and Neutrophils. Finally, LASSO
showed similar strong positive associations with Haemoglobin and Calcium, with
other effects reduced. Coefficients for Lymphocytes, histology and smoking sta-
tus were set to 0. Positive values suggest an increased chance of survival at 6
months, whilst negative values suggest a decreased probability of survival. Ta-
ble 1 shows the accuracies of predictions for these three models using threshold
cutoffs of 0.3 and 0.8 (prediction values below the thresholds are set to 0 and 1
otherwise).
The random forest classifier applied to the EDM dataset achieved an out of
bag (OOB) score (1-error, where error is the average error cross-validated in a
manner similar to k -folds, averaged across the ‘bags’ of data on which each tree
was trained) of 83%. This random forest’s relative feature importance (variable
importance) revealed that lab test factors are the most predictive of survival
at 6 months. Age at treatment initiation is also important. Demographics are
relatively less important, including smoking status. While the performance of
this model is promising, the data included approximately 85% of individuals in
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Method Data Performance
RFC (6-month binary outcome) EMD OOB = 83%
RFC (12-month binary outcome) EMD OOB = 65%
RFR (6-month survival time) EMD R2 = 0.854
RFC (6-month binary outcome) FMI (demographics only) OOB = 63%
RFC (6-month binary outcome) FMI (genomic data only) OOB = 50%
RFC (6-month binary outcome) FMI (all, except lab data) OOB = 63%
Table 2: Performances of a random forest regressor (RFR) and five random forest classifiers
(RFC) on the EDM and FMI datasets
one class and thus, the model did not improve on a naive prediction strategy
based on class weighting.
Random forests were also used for 12 months survival outcome (defined as being
alive 12 months after treatment initiation). Variable importance did not change
substantially relative to the rankings found for 6 months, however the OOB
score dropped to 65%. This is concerning given that a naive prediction strategy
based on class weighting would achieve a score of 75%.
To confirm the validity of the lab test factors observed when predicting 6 and
12 months survival, a random regression forest was used, including the same
predictor variables as the binary outcome models. This model’s relative variable
importance confirmed that lab tests done immediately before CIT initiation are
key prognostic factors for short-term mortality. This model achieved an R2
value of 0.854, indicating that 85% of the variance in observed survival time
within-6-months is explained. This has to be interpreted in light of potential
systematic differences in those who are censored within the first 6 months and
those who survive longer than 6 months (the complement of the set studied in
this analysis).
As for the FMI dataset, a random forest classifier was applied to 6-month binary
survival outcome, each of the demographic data only, genomic data only and
the combination of both, but crucially not lab data. The best performance with
an OOB score of 63% was observed when modelling demographics. We did not
observe any improvement by adding the genomic data to this model. However,
these models did not include lab test variables, which were found to be highly
predictive of survival by the models applied to the EDM dataset. Moreover,
the genomic data were modelled without considering some important biological
variables which might have increased their discriminatory power, and the results
were not corrected for factors such as ancestry. Also, it is worth mentioning that
in this subset of the dataset, the number of features was approximately three
times larger than the number of samples. Table 2 summarises the performances
of these methods.
Figure 1 shows the survival curve for all the patients in the EDM dataset,
generated by the Kaplan-Meier estimator. The vertical and horizontal lines
correspond to the median survival time (see vertical axis), which is 18 months
(see horizontal axis). Figure 2 shows the survival time estimates stratified by
the three histology groups. A logrank test showed significant difference in sur-
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Figure 1: Survival curve (Kaplan-Meier) for patients in the EDM dataset. The vertical and
horizontal axes represent the survival rate and time (months), respectively.
vival times across these histology groups. Figure 3 shows the survival estimates
stratified by quantiles of the Creatinine level. A logrank test showed significant
difference in survival times in the four groups: patients with a Creatinine level
between 0.87 and 1.1 units survived the longest (on average 30.2 months), and
those with the minimum Creatinine level survived the shortest (on average 26.2
months).
A similar analysis showed significant difference in survival times depending on
Albumin, Calcium or Neutrophils levels with p-values (computed by a logrank
test) of <1e-6. The higher the Albumin level, the longer the survival time: the
average survival times are 22.9 months for patients with Albumin levels in the
lowest quartile of the distribution (6.7 to 32 units) and 35.1 months for patients
with Albumin levels in the highest quartile of the distribution (40 to 298 units).
The average difference in survival times with respect to Calcium levels range
from 25.3 months for patients in the lowest quartile (1.08 to 8.7 units) to 30.6
months for patients with a Calcium level between the median and 3rd quartile
of the distribution (9.1 to 9.5 units). The lower the Neutrophils level, the longer
the survival time: on average, 30.3 months for patients with Neutrophils levels
between 0 to 3.6 units and 25.1 months for patients with Neutrophils levels of
8.9 to 5700 units.
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Figure 2: Survival time estimates for patients in the EDM dataset stratified by three histology
groups. The vertical and horizontal axes represent the survival rate and time (months),
respectively.
Figure 3: Survival time estimates for patients in the EDM dataset stratified by quantiles of
the Creatinine level. The vertical and horizontal axes represent the survival rate and time
(months), respectively.
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5 Dynamic Prediction of Patient Survival
5.1 Task Description
In this section, we performed survival analysis using dynamic prediction mod-
els for patients who received CIT as first-line treatment, to be able to model
the relationship between time-varying clinical measures and mortality in these
patients.
5.2 Experimental Setup
Data
• Population: a subset of 11,142 patients from the EDM dataset who had
started CIT as first-line treatment were considered; 6,116 (55%) patients
died over the study period. Mean follow-up was 1.6 years (SD of 1 year
and maximum follow-up of 4.6 years);
• Design: time of CIT initiation was used as entry date. Patients were fol-
lowed up to the earliest of the date of death, the study end date (December
2018) or the last recorded follow-up date, irrespective of any changes in
their treatment or whether immunotherapy was discontinued;
• Baseline measures: the most recent measures prior to the entry date were
extracted;
• Time-varying measures: lab test measures were extracted for each patient
from the study start date to the end of follow-up. We looked at Albu-
min (as serum Albumin has been demonstrated to be a strong predictor
of survival in patients with lung cancer, with low serum Albumin being
associated with reduced survival. 9,421 (85%) patients with a baseline
Albumin measure prior to the index date were eligible for inclusion in the
analysis. After the index date, there were on average 14 time-varying Al-
bumin measures per patient) as well as other prognostic markers including
Haemoglobin, Lactate Dehydrogenase and Neutrophils to Lymphocytes
ratio.
Methods
For survival analysis, we used joint longitudinal-survival models, which allow
investigation of the association between a biomarker’s evolution over time and
survival time. We fitted joint models for Albumin and Haemoglobin, incorpo-
rating all post-baseline measures for each patient (using Weibull baseline hazard
function and shared parameter joint model linked through subject specific ran-
dom effects).
For modelling the relationship between time-varying measures and survival time,
with time horizon of 6 months, we used Cox regression models.
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5.3 Results
Association between Albumin and survival: Time-varying Albumin was
found to be predictive of survival time, according to a Cox regression model
(adjusted for baseline Albumin) reporting a hazard ratio (HR) of 0.96 (95%CI,
lower=0.95, upper=0.97).
A strong association between time-varying Albumin and survival time was also
found by the joint model, reporting a HR of 0.91 (95%CI, lower=0.90, up-
per=0.92).
Association between Haemoglobin and survival: Baseline Haemoglobin
was found to be predictive of survival time, according to a Cox regression
model reporting a HR of 0.94 (95%CI, lower=0.92, upper=0.96). Time-varying
Haemoglobin was also found to be predictive of survival time according to the
Cox regression model (adjusted for baseline Haemoglobin) reporting a HR of
0.90 (95%CI, lower=0.88, upper=0.91).
Similarly, a strong association between time-varying Haemoglobin and survival
time was found by the joint model, reporting a HR of 0.96 (95%CI, lower=0.95,
upper=0.97).
Overall, time-varying Albumin and Haemoglobin levels measured after the ini-
tiation of immunotherapy may be good predictors of future mortality risk.
6 Comparative effectiveness of CIT
6.1 Task Description
In this section, we studied the causal effects of three treatment options: (1)
chemotherapy only, (2) CIT only or (3) combined therapy. We examined the
impact of each type of treatment on patient survival at 6 months after treatment
initiation (first-line), while adjusting for confounding by including all baseline
variables as potential confounders in analyses. In addition, we obtained coun-
terfactual predictions of 6-month survival for each treatment option (this is the
predicted survival had a patient been treated, possibly contrary to fact, with
each of the treatment options). Counterfactual predictions can be used to in-
form decision making when treating new patients.
6.2 Experimental Setup
Data
A subset of 1,887 patients from the FMI dataset were considered (602 patients
were exposed to CIT while 1,285 patients had mono-therapy; 878 patients were
exposed to chemotherapy while 1,009 patients had another type of treatment
involving immunotherapy). The data contain 1,592 distinct variables, including
age, gender, race, histology, smoking status plus variables indicating disease
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progression, additional malignancies, tumour type, tissue of origin and purity
(both pathology and computational estimates), PD-L1 status, ECOG value and
tumour mutational burden (TMB) score. Genomic data were also included.
For some patients, the clinical variables mentioned above were missing. We used
the missingness indicator approach. That is, for missing categorical variables,
an extra category was created to indicate that the value of that variable is
unknown. For missing continuous variables, we performed mean imputation
and created a separate binary missing indicator variable. We the added all
the missing indicator variables to the set of variables available to control for
confounding. This method is valid if the variables with missing data are only
confounders when observed, and not when missing. The genetic features are
available for all the patients.
The treatment options (in terms of combinations of drugs) were defined as
follows:
1. Chemotherapy:
• Carboplatin, Pemetrexed
• Carboplatin, Paclitaxel
2. Immunotherapy:
• Nivolumab
• Pembrolizumab
3. Combined chemotherapy and immunotherapy:
• Bevacizumab, Carboplatin, Pemetrexed
• Carboplatin, Pembrolizumab, Pemetrexed
• Bevacizumab, Carboplatin, Paclitaxel
While there exist many other treatment options, the ones chosen were the most
frequent.
The outcome was 6 months survival, i.e., being alive 6 months after treatment
initiation (binary).
Methods
We estimated the average causal treatment effect for each treatment vs the
others. Due to the presence of confounding by indication (where typically sicker
patients are prescribed the latest treatment), we used causal inference techniques
to obtain unbiased treatment effect estimates, assuming we have adjusted for a
sufficient set of variables to achieve conditional exchangeability (referred to as
no unobserved confounding) in our models. In addition, we made the following
assumptions:
• Positivity: all patients have non-zero probability of being assigned each
treatment option;
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• No unobserved confounders: all variables affecting both the treatment
assignment and outcomes are measured and adjusted for;
• There is no interference between patients.
First, for each treatment vs the union of the other two, we generated a propen-
sity score model, adding all baseline variables as potential confounders. This
propensity score model was fitted using the SuperLearner (SL) algorithm [4], to
avoid unrealistic parametric modelling assumptions. SL is an ensemble of algo-
rithms (e.g., random forests, logistic regression, etc.) which chooses a convex
combination of the trained learners that yields the best performance. We used
5-fold cross validation. The trained SL propensity score model was used to pre-
dict individual propensity scores, to obtain inverse propensity score weighting
and to re-weight the observed data (known as inverse probability weighting -
IPW).
Second, for each treatment option, we also generated data-adaptive (binary)
outcome models, controlling for all baseline variables as confounders, using the
SL algorithm (same library as before). To do this, we split the data randomly
into training (80%) and test (20%) subsets, and ran the SL algorithm with 5-fold
cross-validation. The generated models were then used to obtain counterfactual
outcome predictions for each treatment option (employing a one-vs-rest strat-
egy). This aims to capture the 6-month survival that each individual would
have had, if possibly contrary to fact, they had been treated with each of the
treatments, in turn. We also ran outcome models using weighted loss functions,
with the weights being the inverse of the estimated propensity scores, wherever
possible (for example, for random forests). This was done so that the outcome
model is “tuned” better in the regions of poor overlap, where the PS weights
are larger. An outcome model was then fitted using the weights in the loss
functions. The parameters for this model were tuned using cross-validation.
6.3 Results
When computing the average treatment effects, the results showed that having
immunotherapy as part of the treatment increases the probability of survival
at 6 months. Figure 4 shows the probability of survival at 6 months for CIT
plus immunotherapy vs chemotherapy treatment options, when using IPW loss
functions. On the other hand, the results showed that having CIT alone does
not improve the outcome. Figure 5 shows the probability of survival at 6 months
for CIT vs chemotherapy plus immunotherapy treatment options. These can be
interpreted as counterfactual predictions of survival, had the patient followed
the corresponding treatment (possibly contrary to fact).
The SL algorithm selected the Ranger algorithm [5] (a fast implementation
of random forests for high-dimensional data) as the best performing method.
Figure 6 shows the estimated risks for each method. For a single SL run, we
obtained the predicted probability of survival at 6 months after CIT vs either
monotherapy. Figure 7 shows the density of probability of survival.
15
Figure 4: Probability of survival at 6 months in patients treated with CIT plus immunotherapy
compared to that of patients treated with chemotherapy
Figure 5: Probability of survival at 6 months in patients treated with CIT compared to that
of patients treated with chemotherapy plus immunotherapy
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Figure 6: Estimated risks for each method used in SuperLearner
Figure 7: Density of probability of survival at 6 months in patients treated with CIT compared
to that of patients not treated with CIT
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7 Treatment heterogeneity
We explore treatment heterogeneity, aimed at explaining why some patients re-
spond better to treatment, and characterising which features seem to contribute
to patient response. This section reports our efforts to answer the third question
set in Section 1.3.
7.1 Causal forests
For this, we used the same data as the causal inference analyses above.
Methods
Recent causal machine learning methods to test for treatment effect heterogene-
ity in a data-adaptive manner and avoid overfitting have been proposed. Here,
we focused on the generalisation of causal forests presented by [6]. Causal forests
adapt the random forests algorithm to train in a way that maximises heterogene-
ity in the estimated (or predicted) treatment effect, as opposed to minimising
RMSE in outcome prediction. Causal forests also incorporate sample splitting
so that the trees are honest, meaning we have valid confidence intervals. The
generalised random forests framework improves on the original causal forests by
also incorporating an orthogonalisation step to deal with confounding.
Briefly, separate random forests are built for treatment and outcome on all the
potential baseline confounders. Then, predicted treatment assignment (from
the propensity score random forest predictions) and predicted outcome are used
to obtain residualised “outcomes” for our next models. These residuals are
the difference between the observed quantity and its corresponding prediction.
These residuals are used as outcomes in a second step, for building causal forests.
These residuals can be thought of as a de-confounded version of treatment and
outcome. The use of such residuals as outcomes is common in the doubly robust
literature. A test for treatment heterogeneity is also built into the procedure.
Causal forests perform sample splitting and, therefore, the trees are ‘honest’, i.e.,
they are trained on one part and evaluated on another. In addition, we used the
variable importance feature of the causal forests to explore the variables most
associated with treatment heterogeneity.
Results
We repeated the causal analysis using causal forests for chemotherapy vs any
other treatment option involving immunotherapy. As seen in the plot of individ-
ual treatment effects shown in Figure 8, most patients would have had negative
treatment effects had they been given chemotherapy compared to any other
treatment option involving immunotherapy. As for the heterogeneous effects,
the results showed that after adding the genomic features, treatment effects
are much smaller. We explored the variables associated with treatment effect
heterogeneity, and produced a variable importance plot shown in Figure 9. As
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Figure 8: Individualised treatment effect for chemotherapy compared to other treatment op-
tions involving immunotherapy
Figure 9: Variable importance plot for variables associated with treatment effect heterogeneity
seen in the plot, age, tumour purity and certain genetic mutations are the most
important variables explaining the treatment effect heterogeneity. Due to time
constraints, we did not apply sample splitting.
We produced plots of the individualised treatment effects on age and top three
genetic mutations (LRP1B, TP53 and PTPRD), shown in Figure 10. The ef-
fect of age is quite flat. As seen in the plot, not having mutations in selected
genes results in negative treatment effects with CIT, meaning that it would be
beneficial to not give combination therapy to patients with these mutations.
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Figure 10: Individualised treatment effects on age and top three genetic mutations
7.2 Unsupervised Analysis of Clinical and Genomic Data
Task Description
In this section, we analysed both the clinical and genomic data using unsuper-
vised methods (cluster analysis and data visualisation) to reveal the underlying
structure in the data (e.g., subgroups of patients who benefit more from CIT).
Data
For cluster analysis using hierarchical and spectral clustering and the PAM (or
k -medoids) algorithm as well as for data visualisation, we focused on patients
in the EDM and FMI datasets who received CIT as first-line treatment.
For integrative cluster analysis, we used the data on copy number variants
(CNVs) and single nucleotide variants (SNVs), filtered to select patients who
received CIT but not until after their first-line treatment. Ad-hoc feature se-
lection was performed by selecting the 100 most variant genes across the EDM
and FMI datasets. Figure 11 displays a heatmap showing the SNV data follow-
ing feature selection to select the 100 most variant genes. Similarly, Figure 12
displays a heatmap showing the CNV data following feature selection to select
the 100 most variant genes.
Methods
We used a number of unsupervised clustering and dimensionality reduction tech-
niques including hierarchical and spectral clustering, the PAM algorithm [2] and
the t-SNE algorithm [3]. These methods were applied to two subsets of the data:
the clinical data (the EDM dataset minus the lab test data and the FMI dataset
minus the genomic data) and the clinical data plus the genomic features (from
the FMI dataset).
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Figure 11: Heatmap of the SNV data
Figure 12: Heatmap of the CNV data
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The parameters for these methods were set as follows: for hierarchical and
spectral clustering, Euclidean distance and the RBF kernel were used to compute
the distances and similarities, respectively. Perplexity and number of iterations
for the t-SNE algorithm were set to 30 and 500, respectively.
In the case of hierarchical and spectral clustering and the t-SNE algorithm ap-
plied to the clinical data plus the genomic features, columns containing missing
values were omitted while non-numeric values were converted to numeric ones.
An approach designed to overcome the limitations of clustering mixed data
types was employed using the Gower distance, partitioning around medoids and
silhouette width (an internal validation metric used as an aggregated measure
of how similar an observation is to its own cluster compared to its closest neigh-
bouring cluster). To compute the Gower distance, for each variable type an
appropriate distance metric was used and scaled to fall between 0 and 1. Then,
A linear combination employing user-specific weights was used to compute the
final distance matrix. The matrices used for each variable type were as follows:
• quantitative (interval): range-normalised Manhattan distance;
• ordinal: variable is first ranked and the Manhattan distance is then used
with an adjustment for ties;
• nominal: first, variables of n categories are converted to n binary columns
and then the Dice coefficient is used.
Due to the existence of custom distance matrices, partitioning around medoids
was chosen as the clustering algorithm. The PAM algorithm is more robust
to noise and outliers compared to the k -means, and offers the added benefit of
having an observation serve as the exemplar for a cluster. To determine the
number of clusters (k=5), we used silhouette width.
Integrative cluster analysis was performed using particleMDI [7], an algorithm
that uses particle Monte Carlo methods to infer a shared cluster structure across
multiple datasets. In contrast to many other methods, particleMDI does not
enforce strict agreement in cluster allocations across all datasets, instead allow-
ing cluster structure in one dataset to inform the cluster structure in the others.
The maximum number of clusters, the number of particles, the proportion of
allocations assumed known in each iteration and the number of iterations were
set to 10, 32, 0.33 and 1000, respectively. The output of particleMDI can be
visualised via a posterior similarity matrix (PSM), an n× n matrix with entry
(i, j) indicating how frequently patients i and j (of n total patients) are assigned
to the same cluster. A consensus cluster allocation across datasets can then be
reached by taking the average of individual PSM values across datasets and
performing hierarchical cluster analysis on the corresponding similarity matrix.
Results
Hierarchical and spectral clustering did not produce good clusterings (low sil-
houette coefficients) and hence, their outputs were not considered for further
analysis. The t-SNE algorithm also did not produce distinct clusters. Note that
when visualising the Euclidean distances prior to running t-SNE, we observed
a high correlation between a subset of features.
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Figure 13: Result of clustering the clinical data using the PAM algorithm
Figure 14: Heatmaps of the PSMs for the SNV and CNV data generated by the particleMDI
algorithm. Patients are presented along both axes.
The PAM algorithm applied to the clinical data allowed for clustering of patients
in nearly five distinct clusters. The result is shown in Figure 13. We extracted a
summary of each cluster: for instance, cluster one comprises of majority white
females with history of smoking and non-squamous cell carcinoma and a life
span of 303 days (median), while cluster five comprises of older white males
with history of smoking and squamous cell carcinoma whose life span is nearly
6 months longer (465 days median). The PAM algorithm applied to the clinical
data plus the genomic features, however, did not produce any clustering.
As for the integrative cluster analysis, the consensus cluster allocation suggests
the likely existence of five clusters across the datasets. Interestingly, there ap-
pears to be reasonable agreement in the structure across datasets, with the SNV
data providing some additional specificity on the clusters inferred from the CNV
data. Figure 14 displays a heatmap showing the frequency with which pairs of
patients are assigned to the same cluster. The clusters inferred, however, do
not appear to offer any clinical insights in relation to the relative survival times
across patient groups.
Due to time constraints, we did not investigate the inferred clusters further.
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However, evaluating the differences in survival curves for these clusters can lead
to useful inputs for deciding upon patients who may particularly benefit from
being treated with CIT.
8 Future Work and Research Avenues
The following research avenues were proposed by the data study participants:
• Additional data pre-processing including improved preparation of the ge-
nomic data;
• Inclusion of socioeconomic features: insurance data were available in both
datasets, but were not used in any of the models. However, insurance
category is a strong indicator of socioeconomic status which may have
prognostic relevance (it was observed that many patients changed their
insurance provider during the course of treatment);
• Extension of the analyses to other patient cohorts: for instance, can we
predict survival for patients who have not received CIT at all? or can we
predict patient response to CIT if the patient has been given other treat-
ments previously? Moreover, analyses using causal inference techniques
can be repeated for smaller time windows, i.e., discretising the survival
time and obtaining predictions for the binary outcomes, which will allow
using time-varying confounders. Such analysis can also be repeated for
other lines of treatment (known as treatment intensification), exploiting
the longitudinal aspect of the data to find optimal treatments (known as
optimal dynamic treatment regimes or optimal policy learning);
• Optimisation of methods: due to time constraints, parameters for some of
the methods were not tuned. Tuning the parameters for various methods
and repeating the analyses using the features selected by feature selection
methods can be performed. For dynamic prediction of patient survival,
more complex joint models to evaluate other aspects of biomarker trajec-
tory (e.g., slope or AUC, and adjustment for other baseline measures) and
landmarking models that incorporate multiple time-varying measures can
be employed;
• Application of other methods (e.g., Bayesian methods).
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